Alternatively, if it is assumed that tau seeding is the primary driver of cognitive decline and occurs early in the disease course, it may be reasonable to initiate anti-tau therapy first and discontinue it earlier, particularly if it proves to be highly effective. The gene discussed is MAPT; the disease is Mental deterioration.